|Sample Collection Complete||Data Publicly Available|
What is invasive urothelial bladder cancer?
Urothelial bladder cancer is the most common type of bladder cancer. The bladder is a hollow organ that holds liquid waste, or urine, produced by the kidneys. Invasive bladder cancer develops in the inner lining of the bladder wall and grows finger-like projections, called papillary tumors, into the hollow part of the bladder. In 2010, it was estimated that 70,500 people would be diagnosed with bladder cancer and an estimated 15,000 would die from it.1 Urothelial bladder cancer is more common among men than women. From 2003-2007, the median age of death from bladder cancer was 78 years of age. If the cancer is diagnosed after it has metastasized, as few as five percent of patients will be living five years after diagnosis. View additional information on urothelial bladder cancer.
What types of discoveries about invasive urothelial bladder cancer do The Cancer Genome Atlas (TCGA) researchers hope to make?
- Pinpoint unique genomic changes that predict responsiveness to therapy, particularly BCG, a common biological therapy
- Establish the relationship between genomic changes and lymph node metastasis
- Identify difference in genomic changes in smokers and non-smokers
Where can I find more information about the TCGA Research Network’s studies or studies using TCGA data?
Where can I find clinical trials to treat urothelial bladder cancer that are supported by the National Cancer Institute (NCI)?
View a list of NCI-supported urothelial bladder cancer clinical trials that are now accepting patients.
1American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society, 2010.